Anterior gradient 2 (AGR2): Blood‐based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype
The Prostate2012Vol. 73(3), pp. 306–315
Citations Over TimeTop 10% of 2012 papers
Kian Kani, Paymaneh D. Malihi, Yuqiu Jiang, Haiying Wang, Yixin Wang, Daniel Ruderman, David B. Agus, Parag Mallick, Mitchell E. Gross
Abstract
We conclude that AGR2 expression is elevated at the mRNA and protein level in patients with metastatic prostate cancer. In particular, we find that AGR2 expression is associated features consistent with neuroendocrine, or anaplastic, prostate cancer, exemplified by an aggressive clinical phenotype without elevation in circulating PSA levels. Further studies are warranted to explore the mechanistic and prognostic implications of AGR2 expression in this patient population.
Related Papers
- → Increased expression of prostate‐specific G‐protein‐coupled receptor in human prostate intraepithelial neoplasia and prostate cancers(2004)63 cited
- → Reduced expression of NGEP is associated with high-grade prostate cancers: a tissue microarray analysis(2013)50 cited
- → hTERT and DD3/PCA3 gene expression in prostatic tissues: differentiation between normal prostate, benign prostate hyperplasia and prostate tumours(2002)2 cited
- Expression of Prostate Stem Cell Antigen and Prostate Special Antigen in Prostate Adenocarcinoma Tissues and Its Significance(2005)